Contineum Therapeutics (CTNM) Common Equity (2023 - 2026)

Contineum Therapeutics' Common Equity history runs 4 years deep, the most recent figure standing at $239.7 million for Q2 2026.

• In Q2 2026, Common Equity rose 39.83% year-over-year to $239.7 million; the TTM figure through Jun 2026 stood at $239.7 million (up 39.83% YoY), while the FY2025 annual figure was $261.0 million, up 31.77% from the prior year.
• Common Equity for Q2 2026 stood at $239.7 million, down from $250.0 million in the prior quarter.
• The five-year high for Common Equity was $261.0 million in Q4 2025, with the low at -$97.5 million in Q1 2023.
• The 4-year median for Common Equity is $182.6 million (2025), against an average of $111.1 million.
• The sharpest annual moves came in 2024 and 2025: Common Equity surged 492.38% in 2024, then declined 21.2% in 2025.
• Contineum Therapeutics' Common Equity stood at -$67.9 million in 2023, then jumped by 391.55% to $198.1 million in 2024, then soared by 31.77% to $261.0 million in 2025, then declined by 8.17% to $239.7 million in 2026.
• Business Quant data shows CTNM's Common Equity at $239.7 million in Q2 2026, $250.0 million in Q1 2026, and $261.0 million in Q4 2025.